Churg-Strauss Syndrome: A Comprehensive Medical Guide

Introduction & Overview

Churg-Strauss Syndrome (CSS), also known as Eosinophilic Granulomatosis with Polyangiitis (EGPA), is a rare, multisystemic inflammatory disorder characterized by the triad of asthma, hypereosinophilia, and systemic vasculitis. This complex condition primarily affects small and medium-sized blood vessels, leading to a wide spectrum of clinical manifestations that can impact virtually any organ system. While historically associated with the eponym Churg-Strauss, the current nomenclature, EGPA, more accurately reflects its underlying pathology as a type of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.

EGPA is a challenging diagnosis, often presenting with vague and overlapping symptoms that can mimic other more common conditions. Early recognition and prompt initiation of immunosuppressive therapy are crucial to prevent irreversible organ damage and improve patient outcomes. This comprehensive guide aims to provide an exhaustive overview of EGPA, covering its clinical definition, etiology, pathophysiology, clinical staging, typical presentation, differential diagnoses, diagnostic modalities, and long-term prognosis, serving as an authoritative resource for clinicians and researchers alike.

Technical Specifications / Mechanisms

Clinical Definition

EGPA is defined by the presence of asthma, eosinophilia (typically >1.5 x 10^9/L in peripheral blood), and necrotizing vasculitis affecting small to medium-sized vessels, often with eosinophilic infiltration. The American College of Rheumatology (ACR) classification criteria for CSS (which are still widely used though EGPA is the preferred term) require the presence of asthma and at least three of the following six features:

• Eosinophilia: Peripheral blood eosinophil count ≥1.5 x 10^9/L.
• Mono- or Polyneuropathy: New-onset or worsening peripheral neuropathy.
• Paranasal Sinus Abnormalities: Radiographic evidence of sinusitis or symptoms suggestive of chronic rhinosinusitis.
• Pulmonary Infiltrates: Transient or migratory pulmonary infiltrates on chest imaging.
• Eosinophilia in Biopsy: Eosinophilic infiltration of a tissue specimen (e.g., blood vessel wall, lung, skin, nerve).
• Cardiac Involvement: New-onset valvular regurgitation, myocardial infarction, or impaired ventricular function on echocardiography.

Etiology

The exact etiology of EGPA remains largely unknown. However, a complex interplay of genetic predisposition, environmental factors, and immune dysregulation is suspected.

• Genetic Factors: Certain human leukocyte antigen (HLA) alleles have been associated with an increased risk of EGPA, suggesting a role for genetic susceptibility in immune response.
• Environmental Triggers:
  • Asthma and Allergic Rhinitis: These conditions are almost universally present in EGPA patients and are considered prodromal or triggering factors.
  • Leukotriene Receptor Antagonists (LTRAs): A significant association has been observed between the initiation or dose escalation of LTRAs (e.g., montelukast, zafirlukast) and the onset or exacerbation of EGPA. The mechanism is not fully understood but may involve altered eicosanoid metabolism or a paradoxical reaction.
  • Infections: While not definitively proven, viral infections (e.g., parvovirus B19) have been implicated as potential triggers in some cases.
• Immune Dysregulation: EGPA is characterized by a dysregulated immune response involving both the innate and adaptive immune systems. This includes:
  • Eosinophil Activation and Recruitment: Eosinophils play a central role, releasing inflammatory mediators, cytotoxic proteins, and cytokines that contribute to tissue damage.
  • Autoimmunity: Many patients are ANCA-positive, particularly for antibodies against myeloperoxidase (MPO-ANCA). However, ANCA can be absent in a subset of patients, highlighting the heterogeneity of the disease. Other autoantibodies, such as IgE, may also be elevated.

Pathophysiology

The pathophysiology of EGPA is multifaceted, involving a cascade of inflammatory events:

1. Allergic Sensitization and Eosinophilia: In genetically susceptible individuals, exposure to allergens or other triggers leads to exaggerated Th2-mediated immune responses, characterized by elevated IgE production and recruitment of eosinophils.
2. Eosinophil Activation and Tissue Infiltration: Eosinophils, once recruited to tissues, become activated and release a variety of toxic substances, including major basic protein (MBP), eosinophil cationic protein (ECP), eosinophil peroxidase (EPO), and reactive oxygen species (ROS). These mediators cause direct damage to endothelial cells, basement membranes, and surrounding tissues.
3. Vasculitis: The inflammatory cascade culminates in inflammation and necrosis of small and medium-sized blood vessels. This vasculitis can affect arteries, arterioles, capillaries, and venules. The eosinophilic infiltration of vessel walls is a hallmark of EGPA.
4. ANCA Production (in some cases): In ANCA-positive EGPA, the immune system targets components of neutrophil granules, such as MPO. This may contribute to the activation of neutrophils and their subsequent release of inflammatory mediators, further perpetuating the vasculitic process.
5. Granuloma Formation: While less prominent than in granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), granulomas, particularly in extrapulmonary sites, can be seen in EGPA.

Clinical Staging/Grading

While no universally accepted staging system exists for EGPA, the Vanderbilt Vasculitis Score and the Five-Factor Score (FFS) are commonly used to assess disease severity and prognosis in systemic vasculitis, including EGPA.

• Vanderbilt Vasculitis Score: This score assesses the extent and severity of organ involvement. It considers factors such as:

  • Constitutional symptoms: Fever, weight loss, malaise.
  • Organ system involvement: Skin, peripheral nervous system, gastrointestinal tract, cardiovascular system, renal system, pulmonary system, central nervous system.
  • Laboratory markers: ESR, CRP, creatinine.

• Five-Factor Score (FFS): Originally developed for polyarteritis nodosa, the FFS has been adapted for EGPA and other systemic vasculitides. It predicts mortality and includes:

  • Age ≥ 65 years
  • Renal insufficiency (serum creatinine > 1.5 mg/dL)
  • Gastrointestinal involvement
  • Cardiac involvement
  • Absence of Ear, Nose, and Throat (ENT) involvement

Patients with a higher FFS have a poorer prognosis.

A more pragmatic clinical approach often categorizes EGPA into two main phenotypes:

• "Asthma-predominant" EGPA: Characterized by prominent asthma and eosinophilia, with limited or no evidence of systemic vasculitis or organ damage beyond the respiratory tract.
• "Systemic Vasculitis-dominant" EGPA: Involves significant vasculitic manifestations affecting multiple organ systems, often with neuropathy, skin lesions, and cardiac or renal involvement.

Standard Presentation

The clinical presentation of EGPA is highly variable and depends on the organs involved. The disease typically evolves in three overlapping phases:

Phase 1: Prodromal Phase (Allergic Rhinitis/Asthma)
This phase can last for months to years and is characterized by:
* Asthma: Typically adult-onset, often severe and difficult to control with standard therapies.
* Allergic Rhinitis/Sinusitis: Recurrent nasal polyps, chronic sinusitis, and allergic symptoms are common.
* Hypereosinophilia: Elevated peripheral blood eosinophil counts are a hallmark.

Phase 2: Eosinophilic Phase (Hypereosinophilia)
This phase is defined by marked eosinophilia in the peripheral blood and tissues. Patients may experience:
* Constitutional Symptoms: Fever, fatigue, weight loss, malaise.
* Organ-specific symptoms related to eosinophilic infiltration:
* Pulmonary: Cough, dyspnea, wheezing, pulmonary infiltrates on imaging.
* Gastrointestinal: Abdominal pain, nausea, vomiting, diarrhea, bleeding.
* Cardiac: Myocarditis, endocarditis, pericarditis, valvular regurgitation, dilated cardiomyopathy, heart failure, myocardial infarction.
* Skin: Purpura, urticaria, nodules, livedo reticularis, eczema.
* Neurological: Peripheral neuropathy (mononeuritis multiplex or symmetric polyneuropathy), cranial nerve palsies, central nervous system involvement (rare).

Phase 3: Vasculitic Phase (Systemic Vasculitis)
This phase is characterized by active vasculitis and organ damage. Symptoms are diverse and depend on the affected vasculature:
* Neuropathy: The most common manifestation in this phase, often presenting as a painful, sensory-motor axonal neuropathy, typically asymmetric (mononeuritis multiplex) but can be symmetric.
* Skin Lesions: Palpable purpura, nodules, ulcers, livedo reticularis.
* Cardiac Involvement: Can be life-threatening, leading to heart failure, arrhythmias, and sudden death. Myocardial infarction can occur due to vasculitis of coronary arteries or thromboembolism.
* Renal Involvement: Glomerulonephritis, often mild, but can progress to renal failure.
* Gastrointestinal Involvement: Ischemia, infarction, bleeding.
* Pulmonary Involvement: Hemorrhage, infarction, interstitial lung disease.
* Central Nervous System Involvement: Stroke, seizures, cranial nerve palsies.

Key Clinical Features Summary:

| Feature | Description